COMP <GO>
CRSP vs LLY // ENTERPRISE SCALE & MARKET CAP
CRISPR Therapeutics AG (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CRSP 1
— LLY 13
▲ ENTERPRISE SCALE & MARKET CAP LEADER: LLY
LAST: $51.42 (-5.23%) • MKT CAP: $5.25B
market-cap
$5.25B
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
market-cap
$1.33T
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | 32.36% | -62.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | 2.30% | -8.89 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 45.51% | -110.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 9.29 | -1.32 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.77% | +0.53 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 77.9 | -30.28 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.51 | +0.61 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 26.3x | +1.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $5.25B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | LLY REV | CRSP GROSS % | LLY GROSS % | CRSP FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $65.18B | 44.0% | 83.0% | -$345.9M | $16.81B |
| FY 2024 | $37.3M | $45.04B | 44.0% | 81.3% | -$144.7M | $8.82B |
| FY 2023 | $371.2M | $34.12B | 44.0% | 79.3% | -$277.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
LLY // BETA 0.51